Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1405509 | 0.78 | NOTUM (0.36) | NOTUMPARP10CDK2PARP1DRD2 | |
| SCHEMBL30768024 | 0.78 | NOTUM (0.36) | NOTUMPARP10CDK2PARP1DRD2 | |
| SCHEMBL31443670 | 0.78 | DRD2 (0.37) | NOTUMALDH1A1MAPTPARP10PARP11 | |
| SCHEMBL14234585 | 0.78 | DRD2 (0.37) | NOTUMALDH1A1MAPTPARP10PARP11 | |
| SCHEMBL26656341 | 0.78 | HTR1D (0.38) | NOTUMALDH1A1MAPTPARP10PARP11 | |
| SCHEMBL15300757 | 0.76 | NOTUM (0.32) | NOTUMALDH1A1MAPT | |
| SCHEMBL26431777 | 0.73 | ALDH1A1 (0.34) | NOTUMALDH1A1MAPTPARP10PARP11 | |
| SCHEMBL1613135 | 0.73 | HTR2A (0.39) | — | |
| SCHEMBL18304941 | 0.73 | PARP10 (0.53) | PARP10PARP11CDK2PARP1 | |
| SCHEMBL30362890 | 0.73 | PARP10 (0.53) | PARP10PARP11CDK2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119370-A1 | BRD4-JAK2 INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119370-A1 | BRD4-JAK2 INHIBITORS | BRD4, BICRA, JAK2 | NOTUM 4279/4885ALDH1A1 4036/4885MAPT 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.